China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.

 

The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.

 

The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.

 

Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.

 

Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.

 

Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.

 

More Information About Povorcitinib Phosphate Tablets

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.

 

A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).

 

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

 

Reference

1、China Insights Consultancy (CIC) report

2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.

AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.

The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“

Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.

“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“

The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.

Media Contact

Company: AI Labs

Contact: Media Team

Email: ryan@academic-labs.org

Website: https://ai-labs.live/

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.

 

The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.

 

The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.

 

Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.

 

Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.

 

Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.

 

More Information About Povorcitinib Phosphate Tablets

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.

 

A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).

 

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

 

Reference

1、China Insights Consultancy (CIC) report

2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.

AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.

The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“

Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.

“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“

The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.

Media Contact

Company: AI Labs

Contact: Media Team

Email: ryan@academic-labs.org

Website: https://ai-labs.live/

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

Hashi Mainnet is Live With 20-Plus Partners, Bringing Bitcoin Finance to Sui at Scale

Grand Cayman, Cayman Islands, November 19th, 2026, Chainwire

Anchorage Digital, Fluid, HoneyB, and Upshift support institutional and retail access to Bitcoin on Sui with BitGo, Inc. expected to follow in 2027

Hashi, Sui’s native Bitcoin finance infrastructure, is now live on mainnet, with more than 20 custody, retail, and DeFi participants.

Bitcoin has spent years becoming one of the world’s largest pools of capital. Now the infrastructure to put it to work has arrived, forming one of the broadest coalitions in Bitcoin finance. 

That coalition is still growing fast. The latest to join Hashi are Merkl, an onchain incentive platform; and Current, a lending protocol. These additions expand the ecosystem of DeFi products and services being built around Bitcoin on Sui.

Bitcoin-Native Finance, Now Live

Hashi keeps Bitcoin on the Bitcoin network and mints hBTC, a 1:1 Bitcoin-backed asset, on Sui. That hBTC can then serve as collateral for lending, borrowing, and other onchain financial products. 

Hashi is decentralized by design. It’s secured by validators, not a single entity, using industry-leading cryptography. On top of that foundation, it connects leading providers across custody, trading, and decentralized finance to build financial products, giving Bitcoin holders many ways to put their assets to work.

Accessing Bitcoin Finance on Sui

With hBTC now live, Bitcoin holders have a new set of opportunities at their fingertips. That starts with borrowing against BTC and accessing new financial strategies through lending markets and vaults. 

To meet the specific needs of institutions, several new providers are offering new lending and vault facilities. 

Fluid’s institutional-grade lending protocol is now live on Sui, beginning with Bitcoin-backed stablecoin loans. Bitcoin holders can use Hashi to bring BTC onto Sui as hBTC, then use it as collateral on Fluid to borrow stablecoins, starting with USDC with more flows coming. 

“Bitcoin is the largest pool of idle capital in crypto,” said Samyak Jain, founder and CEO at Fluid. “With Hashi, it can now power deep, capital-efficient credit markets on Fluid.”

Institutional Access, Retail Opportunities, and Liquidity

For institutions, that infrastructure shows up as a custody problem solved. Institutions will be able to use both leading crypto custodians, Anchorage Digital and BitGo, Inc. (“BitGo”) to access Hashi. This model gives institutions a path to hold or deploy BTC into Hashi. Previously announced institutional partners, such as Cumberland and Wave Digital Assets will all play roles as early participants in deploying BTC and stablecoins on Hashi, providing liquidity to a variety of strategies on Sui. Sui DeFi protocols, including Blueprint Finance (Concrete), Bluefin, Cetus, Current, and Suilend will also unlock new lending opportunities, stablecoin credit, and yield strategies backed by Bitcoin. 

“Some of the world’s largest Bitcoin holders are sitting on enormous amounts of untapped financial potential,” said Nathan McCauley, CEO and Co-Founder at Anchorage Digital. “Hashi gives our institutional clients a new way to access Bitcoin finance on Sui, with their BTC held in custody at Anchorage Digital Bank.”

If you’re an institution interested in deploying BTC or stablecoins on Hashi, please reach out to your custodian or hashi@sui.io. Users can explore more at sui.io/hashi. 

About Sui

Sui, where money moves as freely as messages, is a next-generation Layer 1 blockchain built for agentic finance and scalable global payments. Founded by the core team behind Meta’s stablecoin initiative and powered by an object-centric model, Sui makes assets, permissions, and user data programmable and ownable. Sui’s primitives offer builders everything they need to create high-performance payments and financial applications, including instant agentic payments. Learn more at sui.io. 

Contact

Sui Foundation
media@sui.io

neoseek Builds on a Decade of Engineering Expertise to Accelerate Global Expansion in Portable Charging

Building on established engineering capabilities, international design recognition, and product innovation, neoseek is expanding its global reach with portable charging solutions.

Hong Kong, China, 19th Nov 2026 – neoseek, an international charging brand developed by MIIIW Technology, is strengthening its presence across the United States, Europe, and other international markets.

Drawing on more than a decade of consumer electronics design, engineering, and product development experience, the brand is expanding its portable charging portfolio to address changing global consumer requirements.

Since 2015, the expertise behind neoseek has supported the development of charging technologies combining performance, portability, and practical functionality.

As MIIIW Technology’s international charging brand, neoseek builds on established research and manufacturing capabilities while developing products for global markets.

Engineering Heritage and Manufacturing Capabilities 

MIIIW Technology’s engineering experience spans fast-charging protocols, intelligent power distribution, battery management, and thermal engineering.

Its intelligent dynamic power allocation technology supports power distribution between compatible connected devices, while charging temperature-control algorithms help manage operating conditions.

Battery protection systems, thermal management, and structural engineering also form important parts of its development activities. These capabilities support the design of portable charging products that balance output performance with considerations for battery safety and product construction.

MIIIW operates three R&D centres in Beijing, Nanjing, and Shenzhen, with technical personnel representing more than 65% of its workforce. Its manufacturing operations are supported by supply chain management, component selection, hardware and software testing, and production quality controls.

Market Performance and International Design Recognition

The engineering and manufacturing experience behind neoseek is reflected in several company-reported milestones. Charging products developed through its supporting partner network have achieved cumulative shipments exceeding 12 million units. The brand also reports more than 90 R&D patents and over 10 international design awards, including iF Design Award and Red Dot Design Award recognition.

According to the company’s description of GfK’s 2025 online-channel data, its partners’ charging products ranked No. 1 in online shipment volume and sales revenue. These achievements reflect the broader technical, design, manufacturing, and commercial capabilities supporting neoseek’s development.

“At neoseek, we believe portable power should combine performance, reliability, and thoughtful design. Building on the engineering experience developed since 2015, we are focused on creating charging solutions that meet the evolving needs of consumers around the world.” — Shuijun Yin, CEO of neoseek 

Product Innovation: Performance and Portability

M725 Max — High-Performance Portable Power

The neoseek M725 Max is positioned for high-performance portable charging. Featuring a 27,200mAh battery capacity and up to 165W output, it is designed for professionals, laptop users, and consumers managing multiple electronic devices.

Two built-in cables and additional USB ports support simultaneous charging of compatible devices, while intelligent power distribution helps manage output. With substantial battery capacity and high-power delivery, the M725 Max addresses demanding charging requirements during professional activities, business trips, and extended periods away from conventional power outlets.

M320 Air — Slim Everyday Portability

The neoseek M320 Air focuses on combining everyday portability with substantial battery capacity. Featuring a 20,000mAh battery and up to 45W charging output, it offers a slim design suited to commuters, business users, and travellers.

Its digital battery display allows users to monitor remaining power, while a built-in USB-C cable adds everyday convenience. Unlike the high-output M725 Max, the M320 Air prioritises ease of carrying and practical charging functionality, addressing routine mobile power requirements without compromising its substantial battery capacity.

Global Expansion and Future Direction

Building on MIIIW’s international development, neoseek is extending its reach across markets including the United States, Spain, Japan, South Korea, and other regions.

Customers can access product information through the official neoseek website and its Amazon sales channel.

Looking ahead, neoseek plans to continue investing in charging technology, engineering research, and product design while developing portable power solutions for international consumers.

About neoseek

neoseek is an international consumer charging brand developed by MIIIW Technology, building on engineering and design experience established in 2015. Its portfolio includes power banks, wall chargers, and charging accessories designed for everyday use, professional activities, and travel.

Media Contact

Organization: Miiiw Technology Hongkong Co., Limited

Contact Person: Shuijun Yin

Website: https://neoseektech.com/

Email:
support@neoseektech.com

City: Hong Kong

Country: China

Release id: 50931

View source version on King Newswire:
neoseek Builds on a Decade of Engineering Expertise to Accelerate Global Expansion in Portable Charging

file

Al Wathba Insurance Goes Live with Agentic AI Marking a New Chapter in Its Digital Transformation
  • Al Wathba Insurance reports a 50% reduction in case turnaround time and an expansion of quality-assurance review from a 20 to 30% sample to all cases in scope. The production deployment uses Magure’s MagOneAI platform in Al Wathba Insurance’s cloud environment, with AI models served through Core42 Compass in the UAE.

Abu Dhabi, UAE, November 19, 2026, ZEX PR WIRE – Al Wathba Insurance, one of the UAE’s most established national insurers, today announced that agentic AI is live in production across its case management operations – the first milestone in a long-term programme to become an AI-native insurer. The capability is built and governed on MagOneAI, the enterprise agentic AI platform from UAE-headquartered Magure, and runs on sovereign models served through Core42 Compass, a platform that gives developers and enterprise teams secure, scalable access to generative AI through a unified API to leading open and closed-source models.

Customer cases are now read, classified, enriched and routed by AI agents built on MagOneAI that assemble the history a handler would otherwise gather by hand and surface the next best action, while every consequential decision stays with an Al Wathba Insurance professional. Case turnaround has fallen by 50%. Running beneath case management, AI agents also conduct and analyse customer satisfaction surveys in real time and perform quality assurance on case handling – lifting QA coverage from a 20-30% manual sample to 100% of cases reviewed.

Shukri Salem Mussabih Almheiri, Chief Executive Officer of Al Wathba Insurance, said: “For us, AI is not about adding another layer of technology. It is about fundamentally improving how we serve our customers and how our people work. We are building an organisation where technology helps us respond faster, learn from every interaction, and make insurance simpler and more responsive. Starting with real operational use cases allows us to create measurable value today while building the foundation for the Al Wathba Insurance of tomorrow.”

The technology architecture operates within the UAE. The platform runs inside Al Wathba Insurance’s cloud environment, MagOneAI, Magure’s enterprise agentic AI platform, provides orchestration and governance needed, and Core42 Compass serves the models with in-country data residency and private endpoints. Separating the model layer from the orchestration layer also gives Al Wathba Insurance flexibility to adopt appropriate models as the technology evolves without rebuilding its applications or governance framework.

As a licensed insurer, Al Wathba Insurance is governed by the Central Bank of the UAE’s Guidance Note on Consumer Protection and the Responsible Adoption and Use of AI and Machine Learning, which places accountability for AI outcomes at board level and requires fairness, explainability and human oversight of consequential decisions. MagOneAI embeds those requirements at platform level: human task nodes pause any workflow for review or override, and role-based access, monitoring and full audit trails apply across every use case. Personally identifiable information is anonymised before reaching any model, and prompts and outputs are not stored or reused. Magure is ISO 9001, ISO 27001 and ISO 42001 certified with SOC 2 Type II attestation.

Akhil Koka, Chief Executive Officer of Magure, said: “Regulated enterprises shouldn’t have to choose between moving fast and staying compliant. MagOneAI is built so that the governance, human oversight and audit trails are part of the platform from the start. That’s what makes this production-grade, not just a proof of concept.”

That reusable foundation is already proving its value. The workflows running today across case management, customer satisfaction and quality assurance were deployed without separate compliance workstreams for each. Al Wathba Insurance’s next wave of use cases will follow the same path, at a fraction of the cost and time of the first.

Muralikrishnan R, Chief Finance Officer of Al Wathba Insurance, added: “Technology investment must ultimately translate into stronger operations, better controls and sustainable business value. This platform gives us a scalable foundation that can be reused across multiple use cases rather than creating isolated solutions each time. That improves the economics of future deployments while giving us the governance, flexibility and oversight expected of a regulated and listed insurer.”

Core42, a G42 company specialising in sovereign enabled cloud and AI infrastructure, provides the model serving layer for AI deployment. Compass serves the models used by Al Wathba Insurance’s AI agents through private connectivity configured for in-country data residency. This architecture is intended to support Al Wathba Insurance’s UAE residency and sovereign control requirements for the deployed workloads.

Will Badr, Vice President of Product Engineering, Core42, said: “Compass gives Al Wathba Insurance an enterprise grade solution with flexibility to choose the right model for each use case, and to adapt as AI technology evolves, while keeping deployment within a sovereign enabled environment. This helps Al Wathba Insurance maintain UAE data residency and jurisdictional control, while giving the business a high-performance, fully managed foundation to scale AI workloads on demand.”

For customers, the effect is practical: faster resolution, quality that no longer depends on whether a file happened to be audited, and products shaped by evidence from every case and survey rather than a sample of them.

The live workflows are the first in a portfolio that Magure and Al Wathba Insurance plan to develop on MagOneAI. Subject to governance, risk and deployment approvals, the roadmap includes a private AI assistant intended to give employees an approved alternative to public AI tools, followed by medical-underwriting support, first-notice-of-loss triage, and accounts receivable and payable automation.

Koka concluded: “What’s live today isn’t a pilot. It’s production AI doing real work inside a regulated insurer, every day, on a foundation Al Wathba Insurance owns outright with sovereign models served in-country. The hardest part is behind us – from here, every new capability ships on rails that already exist.”